Ocular inflammatory responses in the EP2 and EP4 receptor knockout mice

S Biswas1, P Bhattacherjee, C A Paterson

  • 1Department of Ophthalmology & Visual Science, University of Louisville, KY, USA. s0bisw04@gwise.louisville.edu

Abstract

Insights

EP2 and EP4 receptors play a role in murine ocular inflammation by mediating blood-aqueous barrier disruption and leukocyte infiltration. Blocking EP2 receptors significantly inhibited these effects, while EP4 receptor blockade showed partial effects.

Area of Science:

  • Ophthalmology
  • Immunology
  • Pharmacology

Background:

  • Prostaglandin E2 (PGE2) and its receptors are implicated in inflammatory processes.
  • EP2 and EP4 receptors are key mediators of PGE2 signaling.
  • Understanding their role in ocular inflammation is crucial for developing targeted therapies.

Purpose of the Study:

  • To investigate the specific roles of EP2 and EP4 receptors in the development of murine ocular inflammation.
  • To determine the contribution of these receptors to blood-aqueous barrier disruption and leukocyte infiltration.

Main Methods:

  • Utilized EP2 and EP4 receptor knockout and wild-type mice.
  • Induced ocular inflammation using topical prostaglandin E2, SDF-1, RANTES, and intravitreal lipopolysaccharide.
  • Assessed blood-aqueous barrier integrity by measuring aqueous humor protein levels and leukocyte counts.
  • Visualized vascular leakage using fluorescein angiography.

Main Results:

  • EP2 receptor knockout mice showed significant inhibition of blood-aqueous barrier disruption induced by various inflammatory stimuli.
  • EP4 receptor knockout mice exhibited reduced disruption and leukocyte infiltration after lipopolysaccharide and paracentesis.
  • No significant increase in aqueous humor protein was observed in EP4 knockout mice following prostaglandin E2 treatment.

Conclusions:

  • EP2 and EP4 receptors partially mediate the disruption of the blood-aqueous barrier and leukocyte infiltration in ocular inflammation.
  • These findings highlight the potential of targeting EP2 and EP4 receptors for managing ocular inflammatory conditions.

Related Concept Videos